Analysts Set Veradermics, Incorporated (NYSE:MANE) PT at $153.00

Shares of Veradermics, Incorporated (NYSE:MANE) have been assigned a consensus recommendation of “Moderate Buy” from the nine analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $153.00.

Several brokerages recently weighed in on MANE. Needham & Company LLC boosted their target price on shares of Veradermics from $136.00 to $164.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Jefferies Financial Group upped their price objective on shares of Veradermics from $138.00 to $182.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. B. Riley Financial initiated coverage on shares of Veradermics in a research report on Wednesday, July 15th. They set a “buy” rating and a $170.00 target price on the stock. UBS Group set a $170.00 price target on Veradermics in a report on Wednesday, July 15th. Finally, Lifesci Capital began coverage on Veradermics in a research report on Tuesday, June 16th. They issued an “outperform” rating and a $135.00 price objective for the company.

Veradermics Price Performance

Shares of MANE opened at $113.45 on Friday. The company has a 50-day moving average of $108.67. The stock has a market cap of $4.74 billion and a P/E ratio of -85.95. Veradermics has a 52-week low of $32.00 and a 52-week high of $131.24.

Veradermics (NYSE:MANE) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.76). As a group, equities analysts forecast that Veradermics will post -2.78 EPS for the current fiscal year.

About Veradermics

We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for pattern hair loss, or PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistently plagued with high rates of treatment failure, patient dissatisfaction and treatment discontinuation.